688065 凯赛生物
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,215,08341.49%2,114,1752,441,1042,363,4831,497,191
减:营业总成本1,806,77447.76%1,732,9241,732,1431,671,3061,031,624
    其中:营业成本1,501,85834.13%1,505,4251,580,8411,521,388799,159
               财务费用(63,598)-68.30%(211,491)(295,121)(182,284)(10,928)
               资产减值损失(39,851)149.33%(28,984)(29,545)(4,269)(8,543)
公允价值变动收益----------9,153
投资收益(5,016)-15.98%(7,818)(3,708)16,30418,812
    其中:对联营企业和合营企业的投资收益(5,016)-15.98%(7,818)(3,708)(2,964)--
营业利润389,098-2.37%454,295708,284723,350522,232
利润总额387,372-1.26%448,925695,992724,449520,788
减:所得税费用48,93825.57%40,38983,33790,93763,447
净利润338,434-4.22%408,536612,655633,512457,341
减:非控股权益(6,744)-117.09%42,01159,38938,792(331)
股东净利润345,1779.97%366,524553,266594,719457,672

市场价值指针
每股收益 (元) *0.5909.26%0.6300.9501.0201.180
每股派息 (元) *----0.1900.1800.4500.800
每股净资产 (元) *19.5192.24%19.13718.77125.59524.922
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容